SecBot SecBot
144 ·Filed Sep 2, 2026

PVLA

PALVELLA THERAPEUTICS, INC.
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago SEC0001950047-26-008991
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

The filing is a routine advance notice of a small insider sale. Monitor for the actual Form 4 filing to confirm execution, but the amount is too small to warrant a trading response. No material read-through for the stock.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$155.47
T+0 close · Sep 2, 2026 · via day close
Latest settled
−14.79%
T+20 · $132.47 · next T+60 in 13d
Vs SPY
−13.61%
α at T+20
Latest observation
+17.25%
T+50 · FF3 residual α
  1. T+0 · Sep 3 $155.47entry
  2. T+1 · 2mo ago +1.14%α +1.52% · $157.24
  3. T+5 · 2mo ago −3.43%α −2.29% · $150.13
  4. T+20 · 7w ago −14.79%α −13.61% · $132.47
  5. T+51 · todayOpen
  6. T+60 · in 13d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Christopher Kiritsy filed a Form 144 notice of intent to sell 375 shares of Palvella Therapeutics, valued at approximately $58,875, from a stock option exercise. The proposed sale is immaterial relative to the company's $2.2B market cap and represents a routine insider transaction with no meaningful signal.

Key Facts

  • Insider: Director Christopher P. Kiritsy
  • Proposed sale: 375 shares, estimated value $58,875
  • Shares acquired via stock option exercise on the same date
  • Sale planned for 09/02/2026 on NASDAQ
  • Amount represents ~0.0027% of $2.2B market cap

Financial Impact

Proceeds of ~$58,875 from a director's sale; negligible relative to market cap.

Risk Factors

  • None material, the proposed sale is trivial in size and from a director, not top management.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-008991
Document: 0001950047-26-008991-index.html0001950047-26-008991
Document: 0001950047-26-008991.txt0001950047-26-008991

Track record

36 reports on PVLA

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
  2. Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
  3. Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
  4. Nov 5, 202611d ago Press Release Neutral 6/10 No price data
  5. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
  6. Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  7. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  8. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  9. Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
  10. Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens in 6h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 2, 2026